Our products are available in more than 60 countries; 78% of our revenue is derived from export, 22% from our domestic market. Owing to the well-coordinated operations of our sites in Hungary, our extensive network of external markets, and our subsidiaries and offices operating in 17 countries, we are able to contribute to the treatment of approximately 30 million patients. Our most important markets are the Central Eastern European region, Russia, and the Commonwealth of Independent States.
Since the company's establishment 110 years ago, we have become one of the most significant operators in the Hungarian pharmaceutical market. Based on the number of boxes sold, we have been one of the top 3 suppliers in Hungary.
Egis Group’s product portfolio comprises 642 products. In the 2021/2022 financial year, we distributed medicines of 166 product lines — comprising 149 different active ingredients. Although our main therapeutic areas are the cardiovascular and central nervous system diseases, we also provide modern therapeutic solutions in the fields of oncology and women’s health.